

Domenico PraticÃ²

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6389970/publications.pdf>

Version: 2024-02-01

143
papers

10,774
citations

36303

51
h-index

33894

99
g-index

156
all docs

156
docs citations

156
times ranked

11426
citing authors

#	ARTICLE	IF	CITATIONS
1	Beneficial effects of QTC-4-MeOBnE in an LPS-induced mouse model of depression and cognitive impairments: The role of blood-brain barrier permeability, NF- κ B signaling, and microglial activation. <i>Brain, Behavior, and Immunity</i> , 2022, 99, 177-191.	4.1	18
2	Association of Retromer Deficiency and Tau Pathology in Down Syndrome. <i>Annals of Neurology</i> , 2022, 91, 561-567.	5.3	4
3	1-(7-Chloroquinolin-4-yl)-N-(4-Methoxybenzyl)-5-Methyl-1H-1,2,3-Triazole-4-carboxamide Reduces A β Formation and Tau Phosphorylation in Cellular Models of Alzheimer's Disease. <i>Neurochemical Research</i> , 2022, 47, 1110-1122.	3.3	5
4	The contribution of altered neuronal autophagy to neurodegeneration. , 2022, 238, 108178.		22
5	Gestational high fat diet protects 3xTg offspring from memory impairments, synaptic dysfunction, and brain pathology. <i>Molecular Psychiatry</i> , 2021, 26, 7006-7019.	7.9	7
6	Regional and temporal miRNAs expression profile in a transgenic mouse model of tauopathy: implication for its pathogenesis. <i>Molecular Psychiatry</i> , 2021, 26, 7020-7028.	7.9	10
7	Downregulation of autophagy by 12/15Lipoxygenase worsens the phenotype of an Alzheimer's disease mouse model with plaques, tangles, and memory impairments. <i>Molecular Psychiatry</i> , 2021, 26, 604-613.	7.9	18
8	Effect of QTC-4-MeOBnE Treatment on Memory, Neurodegeneration, and Neurogenesis in a Streptozotocin-Induced Mouse Model of Alzheimer's Disease. <i>ACS Chemical Neuroscience</i> , 2021, 12, 109-122.	3.5	15
9	Extra-virgin olive oil, cognition and brain health. , 2021, , 415-423.		0
10	Endosome Dysregulation in Down Syndrome: A Potential Contributor to Alzheimer Disease Pathology. <i>Annals of Neurology</i> , 2021, 90, 4-14.	5.3	11
11	Targeting autophagy in ischemic stroke: From molecular mechanisms to clinical therapeutics. , 2021, 225, 107848.		105
12	The neurobiology of non-coding RNAs and Alzheimer's disease pathogenesis: Pathways, mechanisms and translational opportunities. <i>Ageing Research Reviews</i> , 2021, 71, 101425.	10.9	49
13	VPS35 Downregulation Alters Degradation Pathways in Neuronal Cells. <i>Journal of Alzheimer's Disease</i> , 2021, 84, 1079-1089.	2.6	5
14	Effects of myocardial ischemia/reperfusion injury on plasma metabolomic profile during aging. <i>Aging Cell</i> , 2021, 20, e13284.	6.7	7
15	Dysregulation of the Retromer Complex in Brain Endothelial Cells Results in Accumulation of Phosphorylated Tau. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 7455-7465.	3.5	5
16	Autophagy Dysfunction in Alzheimer's Disease: Mechanistic Insights and New Therapeutic Opportunities. <i>Biological Psychiatry</i> , 2020, 87, 797-807.	1.3	69
17	Gestational oxidative stress protects against adult obesity and insulin resistance. <i>Redox Biology</i> , 2020, 28, 101329.	9.0	4
18	Extra virgin olive oil improves synaptic activity, short-term plasticity, memory, and neuropathology in a tauopathy model. <i>Aging Cell</i> , 2020, 19, e13076.	6.7	24

#	ARTICLE	IF	CITATIONS
19	The Functional Role of microRNAs in the Pathogenesis of Tauopathy. <i>Cells</i> , 2020, 9, 2262.	4.1	9
20	QTC-4-MeOBnE Rescues Scopolamine-Induced Memory Deficits in Mice by Targeting Oxidative Stress, Neuronal Plasticity, and Apoptosis. <i>ACS Chemical Neuroscience</i> , 2020, 11, 1259-1269.	3.5	11
21	Alzheimer's disease: phenotypic approaches using disease models and the targeting of tau protein. <i>Expert Opinion on Therapeutic Targets</i> , 2020, 24, 319-330.	3.4	18
22	A pharmacological chaperone improves memory by reducing A β and tau neuropathology in a mouse model with plaques and tangles. <i>Molecular Neurodegeneration</i> , 2020, 15, 1.	10.8	110
23	Glycogen synthase kinase-3 signaling in Alzheimer's disease. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2020, 1867, 118664.	4.1	225
24	Dysregulation of the Retromer Complex System in Down Syndrome. <i>Annals of Neurology</i> , 2020, 88, 137-147.	5.3	20
25	Learning Impairments, Memory Deficits, and Neuropathology in Aged Tau Transgenic Mice Are Dependent on Leukotrienes Biosynthesis: Role of the cdk5 Kinase Pathway. <i>Molecular Neurobiology</i> , 2019, 56, 1211-1220.	4.0	16
26	Endosomal sorting and trafficking, the retromer complex and neurodegeneration. <i>Molecular Psychiatry</i> , 2019, 24, 857-868.	7.9	59
27	Early-life exposure to high-fat diet influences brain health in aging mice. <i>Aging Cell</i> , 2019, 18, e13040.	6.7	11
28	Impaired mitochondrial calcium efflux contributes to disease progression in models of Alzheimer's disease. <i>Nature Communications</i> , 2019, 10, 3885.	12.8	224
29	Sex-specific neurogenic deficits and neurocognitive disorders in middle-aged HIV-1 Tg26 transgenic mice. <i>Brain, Behavior, and Immunity</i> , 2019, 80, 488-499.	4.1	15
30	Elevated levels of brain homocysteine directly modulate the pathological phenotype of a mouse model of tauopathy. <i>Molecular Psychiatry</i> , 2019, 24, 1696-1706.	7.9	37
31	Antileukotriene therapy by reducing tau phosphorylation improves synaptic integrity and cognition of P301S transgenic mice. <i>Aging Cell</i> , 2018, 17, e12759.	6.7	17
32	Dissecting the Role of 5-Lipoxygenase in the Homocysteine-Induced Alzheimer's Disease Pathology. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1337-1344.	2.6	13
33	Brain 5-lipoxygenase overexpression worsens memory, synaptic integrity, and tau pathology in the P301S mice. <i>Aging Cell</i> , 2018, 17, e12695.	6.7	24
34	Overexpression of 5-Lipoxygenase Worsens the Phenotype of a Mouse Model of Tauopathy. <i>Molecular Neurobiology</i> , 2018, 55, 5926-5936.	4.0	13
35	P2 ¹⁹⁹ : 5LO GENETIC DELETION ATTENUATES NEUROINFLAMMATION IN A P301S MOUSE MODEL OF TAUOPATHY. <i>Alzheimer's and Dementia</i> , 2018, 14, P745.	0.8	2
36	N-acetylcysteine targets 5 lipoxygenase-derived, toxic lipids and can synergize with prostaglandin E ₂ to inhibit ferroptosis and improve outcomes following hemorrhagic stroke in mice. <i>Annals of Neurology</i> , 2018, 84, 854-872.	5.3	195

#	ARTICLE	IF	CITATIONS
37	Novel Key Players in the Development of Tau Neuropathology: Focus on the 5-Lipoxygenase. <i>Journal of Alzheimer's Disease</i> , 2018, 64, S481-S489.	2.6	7
38	The retromer complex system in a transgenic mouse model of AD: influence of age. <i>Neurobiology of Aging</i> , 2017, 52, 32-38.	3.1	27
39	Homocysteine modulates 5-lipoxygenase expression level via DNA methylation. <i>Aging Cell</i> , 2017, 16, 273-280.	6.7	39
40	Extra-virgin olive oil ameliorates cognition and neuropathology of the 3xTg mice: role of autophagy. <i>Annals of Clinical and Translational Neurology</i> , 2017, 4, 564-574.	3.7	56
41	Genetic absence of ALOX5 protects from homocysteine-induced memory impairment, tau phosphorylation and synaptic pathology. <i>Human Molecular Genetics</i> , 2017, 26, 1855-1862.	2.9	10
42	Five lipoxygenase hypomethylation mediates the homocysteine effect on Alzheimer's phenotype. <i>Scientific Reports</i> , 2017, 7, 46002.	3.3	22
43	Effect of canola oil consumption on memory, synapse and neuropathology in the triple transgenic mouse model of Alzheimer's disease. <i>Scientific Reports</i> , 2017, 7, 17134.	3.3	7
44	12/15-Lipoxygenase Inhibition Reverses Cognitive Impairment, Brain Amyloidosis, and Tau Pathology by Stimulating Autophagy in Aged Triple Transgenic Mice. <i>Biological Psychiatry</i> , 2017, 81, 92-100.	1.3	66
45	Reply to comment: Extravirgin olive oil ameliorates cognition and neuropathology of the 3xTg mice. <i>Annals of Clinical and Translational Neurology</i> , 2017, 4, 763-763.	3.7	0
46	The direct role of 5-lipoxygenase on tau pathology, synaptic integrity and cognition in a mouse model of tauopathy. <i>Translational Psychiatry</i> , 2017, 7, 1288.	4.8	27
47	<sc>GATA</sc>1-mediated transcriptional regulation of the β -secretase activating protein increases $A\beta$ formation in Down syndrome. <i>Annals of Neurology</i> , 2016, 79, 138-143.	5.3	15
48	The 5-Lipoxygenase as modulator of Alzheimer's β -secretase and therapeutic target. <i>Brain Research Bulletin</i> , 2016, 126, 207-212.	3.0	24
49	Regulation of gamma-secretase activating protein by the 5Lipoxygenase: in vitro and in vivo evidence. <i>Scientific Reports</i> , 2015, 5, 11086.	3.3	10
50	P4-018: Homocysteine exacerbates Alzheimer's disease neuropathology and cognitive deficit in the 3xTg mice via 5-lipoxygenase DNA hypomethylation. , 2015, 11, P773-P774.		0
51	O2-05-04: The involvement of the 5lipoxygenase pathway in tauopathy. , 2015, 11, P184-P185.		0
52	P3-316: High cholesterol diet during pregnancy attenuates amyloid pathology, cognitive deficit, and synaptic dysfunction in the offspring of 3xTg Alzheimer's disease mice. , 2015, 11, P758-P758.		0
53	Degradation of gamma secretase activating protein by the ubiquitin-proteasome pathway. <i>Journal of Neurochemistry</i> , 2015, 133, 432-439.	3.9	12
54	The 12/15-lipoxygenase as an emerging therapeutic target for Alzheimer's disease. <i>Trends in Pharmacological Sciences</i> , 2015, 36, 181-186.	8.7	69

#	ARTICLE	IF	CITATIONS
55	Glucose deprivation increases tau phosphorylation via p38 mitogen-activated protein kinase. <i>Aging Cell</i> , 2015, 14, 1067-1074.	6.7	32
56	Pharmacologic Inhibition of 5-Lipoxygenase Improves Memory, Rescues Synaptic Dysfunction, and Ameliorates Tau Pathology in a Transgenic Model of Tauopathy. <i>Biological Psychiatry</i> , 2015, 78, 693-701.	1.3	41
57	Gamma Secretase-Activating Protein Is a Substrate for Caspase-3: Implications for Alzheimer's Disease. <i>Biological Psychiatry</i> , 2015, 77, 720-728.	1.3	34
58	Modulation of AD neuropathology and memory impairments by the isoprostane F ₂ is mediated by the thromboxane receptor. <i>Neurobiology of Aging</i> , 2015, 36, 812-820.	3.1	13
59	Memory Decline in Down Syndrome and Its Relationship to iPF2alpha, a Urinary Marker of Oxidative Stress. <i>PLoS ONE</i> , 2014, 9, e97709.	2.5	17
60	Lipid Peroxidation in Psychiatric Illness: Overview of Clinical Evidence. <i>Oxidative Medicine and Cellular Longevity</i> , 2014, 2014, 1-5.	4.0	44
61	Homocysteine exacerbates Aβ amyloid pathology, tau pathology, and cognitive deficit in a mouse model of Alzheimer disease with plaques and tangles. <i>Annals of Neurology</i> , 2014, 75, 851-863.	5.3	100
62	Absence of ALOX5 gene prevents stress-induced memory deficits, synaptic dysfunction and tauopathy in a mouse model of Alzheimer's disease. <i>Human Molecular Genetics</i> , 2014, 23, 6894-6902.	2.9	26
63	Sleep deprivation impairs memory, tau metabolism, and synaptic integrity of a mouse model of Alzheimer's disease with plaques and tangles. <i>Neurobiology of Aging</i> , 2014, 35, 1813-1820.	3.1	165
64	Overexpression of 12/15-lipoxygenase increases anxiety behavior in female mice. <i>Neurobiology of Aging</i> , 2014, 35, 1032-1036.	3.1	6
65	Novel lipid signaling pathways in Alzheimer's disease pathogenesis. <i>Biochemical Pharmacology</i> , 2014, 88, 560-564.	4.4	33
66	Neuroinflammation and Alzheimer's disease: lessons learned from 5-lipoxygenase. <i>Translational Neuroscience</i> , 2014, 5, .	1.4	11
67	Modulation of lipopolysaccharide-induced memory insult, γ-secretase, and neuroinflammation in triple transgenic mice by 5-lipoxygenase. <i>Neurobiology of Aging</i> , 2014, 35, 1024-1031.	3.1	26
68	Zileuton restores memory impairments and reverses amyloid and tau pathology in aged Alzheimer's disease mice. <i>Neurobiology of Aging</i> , 2014, 35, 2458-2464.	3.1	58
69	Pharmacological Modulation of GSAP Reduces Amyloid-β Levels and Tau Phosphorylation in a Mouse Model of Alzheimer's Disease with Plaques and Tangles. <i>Journal of Alzheimer's Disease</i> , 2014, 41, 729-737.	2.6	27
70	High Levels of Homocysteine Results in Cerebral Amyloid Angiopathy in Mice. <i>Journal of Alzheimer's Disease</i> , 2014, 43, 29-35.	2.6	33
71	O ₁ : SLEEP DEPRIVATION IMPAIRS MEMORY, TAU METABOLISM, AND SYNAPTIC INTEGRITY OF A MOUSE MODEL OF ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2014, 10, P268.	0.8	1
72	The 5-lipoxygenase pathway: oxidative and inflammatory contributions to the Alzheimer's disease phenotype. <i>Frontiers in Cellular Neuroscience</i> , 2014, 8, 436.	3.7	60

#	ARTICLE	IF	CITATIONS
73	The 12-lipoxygenase is a modulator of Alzheimer's-related tau pathology <i>in vivo</i> . <i>Aging Cell</i> , 2013, 12, 1082-1090.	6.7	37
74	5-Lipoxygenase pharmacological blockade decreases tau phosphorylation <i>in vivo</i> : involvement of the cyclin-dependent kinase-5. <i>Neurobiology of Aging</i> , 2013, 34, 1549-1554.	3.1	24
75	The involvement of 5-lipoxygenase activating protein in anxiety-like behavior. <i>Journal of Psychiatric Research</i> , 2013, 47, 694-698.	3.1	16
76	The Influence of 5-Lipoxygenase on Alzheimer's Disease-Related Tau Pathology: In Vivo and In Vitro Evidence. <i>Biological Psychiatry</i> , 2013, 74, 321-328.	1.3	26
77	Knockout of 5-lipoxygenase prevents dexamethasone-induced tau pathology in 3xTg mice. <i>Aging Cell</i> , 2013, 12, 706-711.	6.7	19
78	5-Lipoxygenase Activating Protein Reduction Ameliorates Cognitive Deficit, Synaptic Dysfunction, and Neuropathology in a Mouse Model of Alzheimer's Disease. <i>Biological Psychiatry</i> , 2013, 74, 348-356.	1.3	40
79	Zileuton Improves Memory Deficits, Amyloid and Tau Pathology in a Mouse Model of Alzheimer's Disease with Plaques and Tangles. <i>PLoS ONE</i> , 2013, 8, e70991.	2.5	48
80	Stress Hormone Leads to Memory Deficits and Altered Tau Phosphorylation in a Model of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 31, 167-176.	2.6	55
81	Alzheimer's Disease and the Quest for its Biological Measures. <i>Journal of Alzheimer's Disease</i> , 2012, 33, S237-S241.	2.6	6
82	Involvement of 5-lipoxygenase activating protein in the amyloidotic phenotype of an Alzheimer's disease mouse model. <i>Journal of Neuroinflammation</i> , 2012, 9, 127.	7.2	27
83	Adeno-associated virus-mediated brain delivery of 5-lipoxygenase modulates the AD-like phenotype of APP mice. <i>Molecular Neurodegeneration</i> , 2012, 7, 1.	10.8	96
84	Vitamin E in aging, dementia, and Alzheimer's disease. <i>BioFactors</i> , 2012, 38, 90-97.	5.4	73
85	Transcriptional regulation of β -secretase by 12/15-lipoxygenase results in enhanced amyloidogenesis and cognitive impairments. <i>Annals of Neurology</i> , 2012, 71, 57-67.	5.3	31
86	Pharmacologic Blockade of 5-Lipoxygenase Improves the Amyloidotic Phenotype of an Alzheimer's Disease Transgenic Mouse Model. <i>American Journal of Pathology</i> , 2011, 178, 1762-1769.	3.8	77
87	Is hyperhomocysteinemia an Alzheimer's disease (AD) risk factor, an AD marker, or neither?. <i>Trends in Pharmacological Sciences</i> , 2011, 32, 562-571.	8.7	140
88	The Oral Iron Chelator Deferiprone Protects against Iron Overload-Induced Retinal Degeneration. , 2011, 52, 959.		101
89	5-lipoxygenase as an endogenous modulator of amyloid beta formation <i>in vivo</i> . <i>Annals of Neurology</i> , 2011, 69, 34-46.	5.3	87
90	Involvement of 5-Lipoxygenase in the Corticosteroid-Dependent Amyloid Beta Formation: In Vitro and In Vivo Evidence. <i>PLoS ONE</i> , 2011, 6, e15163.	2.5	19

#	ARTICLE	IF	CITATIONS
91	Knockout of 5-Lipoxygenase Results in Age-Dependent Anxiety-Like Behavior in Female Mice. PLoS ONE, 2011, 6, e29448.	2.5	16
92	Acceleration of brain amyloidosis in an Alzheimer's disease mouse model by a folate, vitamin B6 and B12-deficient diet. Experimental Gerontology, 2010, 45, 195-201.	2.8	73
93	Severe In Vivo Hyper-Homocysteinemia is not Associated with Elevation of Amyloid- β Peptides in the Tg2576 Mice. Journal of Alzheimer's Disease, 2010, 21, 133-140.	2.6	11
94	Normalization of hyperhomocysteinemia improves cognitive deficits and ameliorates brain amyloidosis of a transgenic mouse model of Alzheimer's disease. FASEB Journal, 2010, 24, 3895-3902.	0.5	27
95	Amelioration of the Alzheimer's Disease Phenotype by Absence of 12/15-Lipoxygenase. Biological Psychiatry, 2010, 68, 922-929.	1.3	62
96	The neurobiology of isoprostanes and Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2010, 1801, 930-933.	2.4	56
97	The 5-Lipoxygenase as a Common Pathway for Pathological Brain and Vascular Aging. Cardiovascular Psychiatry and Neurology, 2009, 2009, 1-5.	0.8	33
98	High-Dose B Vitamin Supplements and Alzheimer Disease. JAMA - Journal of the American Medical Association, 2009, 301, 1020.	7.4	3
99	Vascular biology of eicosanoids and atherogenesis. Expert Review of Cardiovascular Therapy, 2009, 7, 1079-1089.	1.5	26
100	High Fruit and Vegetable Intake is Positively Correlated with Antioxidant Status and Cognitive Performance in Healthy Subjects. Journal of Alzheimer's Disease, 2009, 17, 921-927.	2.6	122
101	Evidence of Oxidative Stress in Alzheimer's Disease Brain and Antioxidant Therapy. Annals of the New York Academy of Sciences, 2008, 1147, 70-78.	3.8	272
102	Oxidative stress hypothesis in Alzheimer's disease: a reappraisal. Trends in Pharmacological Sciences, 2008, 29, 609-615.	8.7	473
103	Additive anti-atherogenic effect of thromboxane receptor antagonism with 12/15lipoxygenase gene disruption in apolipoprotein E-deficient mice. Atherosclerosis, 2008, 199, 265-270.	0.8	7
104	Prostanoid and isoprostanoid pathways in atherogenesis. Atherosclerosis, 2008, 201, 8-16.	0.8	47
105	5-Lipoxygenase gene disruption reduces amyloid- β pathology in a mouse model of Alzheimer's disease. FASEB Journal, 2008, 22, 1169-1178.	0.5	152
106	Thromboxane Receptor Activation Mediates Isoprostane-Induced Increases in Amyloid Pathology in Tg2576 Mice. Journal of Neuroscience, 2008, 28, 4785-4794.	3.6	31
107	Thromboxane receptor blockade improves the antiatherogenic effect of thromboxane A2 suppression in LDLR KO mice. Blood, 2007, 109, 3291-3296.	1.4	39
108	The 5-lipoxygenase enzymatic pathway in the mouse brain: Young versus old. Neurobiology of Aging, 2007, 28, 1457-1462.	3.1	95

#	ARTICLE	IF	CITATIONS
109	A role for 12/15 lipoxygenase in the amyloid β precursor protein metabolism. <i>Journal of Neurochemistry</i> , 2007, 103, 070630082917005-???	3.9	32
110	A novel thromboxane receptor antagonist and synthase inhibitor, BM-573, reduces development and progression of atherosclerosis in LDL receptor deficient mice. <i>European Journal of Pharmacology</i> , 2007, 561, 105-111.	3.5	25
111	Coxibs and Alzheimer's disease: Should they stay or should they go?. <i>Annals of Neurology</i> , 2006, 59, 219-228.	5.3	51
112	Coxibs and Cardiovascular Side-Effects: From Light to Shadow. <i>Current Pharmaceutical Design</i> , 2006, 12, 971-975.	1.9	118
113	Chronic melatonin therapy fails to alter amyloid burden or oxidative damage in old Tg2576 mice: implications for clinical trials. <i>Brain Research</i> , 2005, 1037, 209-213.	2.2	100
114	Elevation of 12/15 lipoxygenase products in AD and mild cognitive impairment. <i>Annals of Neurology</i> , 2005, 58, 623-626.	5.3	108
115	Involvement of Thromboxane Receptor in the Proatherogenic Effect of Isoprostane F ₂ I ₂ -III. <i>Circulation</i> , 2005, 112, 2867-2874.	1.6	58
116	Selective Cyclooxygenase-2 Inhibitors Development in Cardiovascular Medicine. <i>Circulation</i> , 2005, 112, 1073-1079.	1.6	43
117	Antioxidants and endothelium protection. <i>Atherosclerosis</i> , 2005, 181, 215-224.	0.8	69
118	Increase in peripheral oxidative stress during hypercholesterolemia is not reflected in the central nervous system: evidence from two mouse models. <i>Neurochemistry International</i> , 2005, 46, 435-439.	3.8	17
119	Absence of 12/15 Lipoxygenase Reduces Brain Oxidative Stress in Apolipoprotein E-Deficient Mice. <i>American Journal of Pathology</i> , 2005, 167, 1371-1377.	3.8	41
120	Thromboxane, prostacyclin and isoprostanes: therapeutic targets in atherogenesis. <i>Trends in Pharmacological Sciences</i> , 2005, 26, 639-644.	8.7	90
121	Peripheral biomarkers of oxidative damage in Alzheimer's disease: the road ahead. <i>Neurobiology of Aging</i> , 2005, 26, 581-583.	3.1	35
122	Early Vitamin E supplementation in young but not aged mice reduces A β levels and amyloid deposition in a transgenic model of Alzheimer's disease. <i>FASEB Journal</i> , 2004, 18, 323-325.	0.5	288
123	Vitamin E reduces amyloidosis and improves cognitive function in Tg2576 mice following repetitive concussive brain injury. <i>Journal of Neurochemistry</i> , 2004, 90, 1541-1541.	3.9	1
124	Vitamin E reduces amyloidosis and improves cognitive function in Tg2576 mice following repetitive concussive brain injury. <i>Journal of Neurochemistry</i> , 2004, 90, 758-764.	3.9	147
125	Modulation of Nuclear Factor- κ B Activity by Indomethacin Influences A β Levels but Not A β Precursor Protein Metabolism in a Model of Alzheimer's Disease. <i>American Journal of Pathology</i> , 2004, 165, 2197-2206.	3.8	156
126	12/15-Lipoxygenase Is Increased in Alzheimer's Disease. <i>American Journal of Pathology</i> , 2004, 164, 1655-1662.	3.8	207

#	ARTICLE	IF	CITATIONS
127	Lipid Peroxidation and Oxidative imbalance: Early functional events in Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2004, 6, 171-175.	2.6	206
128	Reduction of brain lipid peroxidation by CSF drainage in Alzheimer's disease patients. <i>Journal of Alzheimer's Disease</i> , 2004, 6, 385-389.	2.6	18
129	Vitamin E Reduces Progression of Atherosclerosis in Low-Density Lipoprotein Receptor-Deficient Mice With Established Vascular Lesions. <i>Circulation</i> , 2003, 107, 521-523.	1.6	75
130	Effect of Low-Dose Aspirin on Vascular Inflammation, Plaque Stability, and Atherogenesis in Low-Density Lipoprotein Receptor-Deficient Mice. <i>Circulation</i> , 2002, 106, 1282-1287.	1.6	212
131	Increase of Brain Oxidative Stress in Mild Cognitive Impairment. <i>Archives of Neurology</i> , 2002, 59, 972.	4.5	574
132	Aluminum modulates brain amyloidosis through oxidative stress in APP transgenic mice. <i>FASEB Journal</i> , 2002, 16, 1138-1140.	0.5	252
133	Repetitive Mild Brain Trauma Accelerates A β Deposition, Lipid Peroxidation, and Cognitive Impairment in a Transgenic Mouse Model of Alzheimer Amyloidosis. <i>Journal of Neuroscience</i> , 2002, 22, 446-454.	3.6	314
134	Alzheimer's disease and oxygen radicals: new insights. <i>Biochemical Pharmacology</i> , 2002, 63, 563-567.	4.4	174
135	Oxidative imbalance and lipid peroxidation in Alzheimer's disease. <i>Drug Development Research</i> , 2002, 56, 446-451.	2.9	9
136	Local and systemic increase in lipid peroxidation after moderate experimental traumatic brain injury. <i>Journal of Neurochemistry</i> , 2002, 80, 894-898.	3.9	63
137	Angioplasty increases coronary sinus F ₂ -isoprostane formation: evidence for in vivo oxidative stress during PTCA. <i>Journal of the American College of Cardiology</i> , 2001, 37, 76-80.	2.8	110
138	Increased Lipid Peroxidation Precedes Amyloid Plaque Formation in an Animal Model of Alzheimer Amyloidosis. <i>Journal of Neuroscience</i> , 2001, 21, 4183-4187.	3.6	752
139	In vivo measurement of the redox state. <i>Lipids</i> , 2001, 36, S45-S47.	1.7	37
140	F ₂ -isoprostanes: sensitive and specific non-invasive indices of lipid peroxidation in vivo. <i>Atherosclerosis</i> , 1999, 147, 1-10.	0.8	167
141	Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in ApoE-deficient mice. <i>Nature Medicine</i> , 1998, 4, 1189-1192.	30.7	496
142	Increased F ₂ -isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo. <i>FASEB Journal</i> , 1998, 12, 1777-1783.	0.5	396
143	Generation of 8-Epi prostaglandin F by Human Monocytes. <i>Journal of Biological Chemistry</i> , 1996, 271, 8919-8924.	3.4	179